Skip to main content
NVDA+1.07%AAPL-0.33%MSFT-0.63%GOOGL-1.06%AMZN+0.78%TSM+1.40%SPCX-0.40%META-0.68%AVGO+2.33%TSLA+1.23%LLY+0.45%BRK-B+1.17%MU+2.54%SKHY+4.09%WMT+0.33%JPM+0.74%AMD+2.80%XOM+0.73%V-0.92%JNJ+0.94%ASMLa+1.77%MA-1.62%ABBV+0.40%INTC+4.04%CVX-0.51%1398.HK+2.15%0700.HK-0.31%COST+0.18%CSCO+3.51%KO-0.01%ORCL-0.08%PG-0.68%UNH-1.77%1816.HK+1.32%BAC-0.08%3988.HK+0.66%HD-0.14%CAT+0.75%0857.HK-0.98%PM+1.20%0939.HK+0.81%AP2d+2.40%AMAT+2.74%1288.HK+0.60%GE+0.98%LRCX+3.22%DELL+2.37%0005.HK-5.56%HSBA.L-6.86%NVS+1.78%NZDJPY+0.69%NZDMXN+0.64%USDJPY+0.61%AUDJPY+0.58%EURNZD-0.55%NZDCHF+0.49%CADJPY+0.49%EURUSD-0.46%AUDDKK+0.44%EURSEK-0.44%EURAUD-0.42%NZDSGD+0.42%USDCHF+0.41%GBPTRY+0.41%AUDCHF+0.40%GBPNZD-0.40%GBPUSD-0.33%GBPHKD+0.32%CHFSEK-0.32%NOKJPY+0.31%EURNOK-0.31%EURCAD-0.30%GBPAUD-0.30%GBPMXN-0.28%CADCHF+0.28%GBPJPY+0.27%EURCNH-0.24%AUDSGD+0.24%USDSEK-0.23%USDMXN+0.23%EURHKD-0.22%USDDKK+0.21%CHFJPY+0.21%USDPLN+0.21%NZDCAD+0.21%GBPCAD-0.21%EURZAR-0.20%EURSGD-0.20%SGDJPY+0.19%CHFNOK-0.18%USDTRY+0.18%EURJPY+0.17%USDILS+0.16%USDCAD+0.14%AUDNOK+0.13%EURGBP-0.12%AUDNZD-0.11%AUDCAD+0.10%USDNOK-0.10%GBPSGD-0.09%GBPZAR-0.08%CHFSGD-0.07%GBPCHF+0.07%NZDUSD+0.07%EURCHF-0.06%USDTHB-0.04%USDCOP-0.04%USDHKD+0.03%AUDUSD-0.03%USDCNH-0.03%USDZAR+0.03%USDSGD+0.01%EURCZK+0.01%PLNJPY+0.01%EURPLN0.00%EURDKK0.00%COFFEE-1.83%COCOA+1.20%SUGAR+1.02%HG1+0.94%XPTUSD-0.71%XAGUSD-0.59%GAGUSD-0.59%UKOIL-0.30%USOIL-0.29%GAUUSD+0.15%XAUUSD+0.15%XNGUSD+0.14%BTCUSD+0.54%ETHUSD+23.96%USDTUSD+0.01%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.06%ZECUSDT+3.59%DOGEUSD+20.65%XMRUSDT-0.08%LINKUSD+25.58%BCHUSDT+1.65%XLMUSD+0.04%UNIUSD-0.19%LTCUSD+17.89%SUIUSD+0.83%HBARUSDT-0.82%TONUSD+41.71%TAOUSDT+0.26%AAVEUSD-1.92%DOTUSDT-1.19%ICPUSDT-0.84%ONDOUSDT-0.24%WLDUSDT+0.83%ARBUSDT+0.60%JUPUSDT+0.30%INJUSDT+0.45%ATOMUSDT-0.21%STXUSDT-0.10%TIAUSDT-2.89%PYTHUSDT-2.39%FETUSDT+1.64%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT-0.27%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+1.05%POLUSDT-0.86%AXSUSDT+0.20%EOSUSDT+2.21%FARTCOINUSDT+2.30%DYDXUSDT+0.44%GALAUSDT-0.75%ORDIUSDT+1.02%RONINUSDT+0.02%NOTUSDT+1.92%NVDA+1.07%AAPL-0.33%MSFT-0.63%GOOGL-1.06%AMZN+0.78%TSM+1.40%SPCX-0.40%META-0.68%AVGO+2.33%TSLA+1.23%LLY+0.45%BRK-B+1.17%MU+2.54%SKHY+4.09%WMT+0.33%JPM+0.74%AMD+2.80%XOM+0.73%V-0.92%JNJ+0.94%ASMLa+1.77%MA-1.62%ABBV+0.40%INTC+4.04%CVX-0.51%1398.HK+2.15%0700.HK-0.31%COST+0.18%CSCO+3.51%KO-0.01%ORCL-0.08%PG-0.68%UNH-1.77%1816.HK+1.32%BAC-0.08%3988.HK+0.66%HD-0.14%CAT+0.75%0857.HK-0.98%PM+1.20%0939.HK+0.81%AP2d+2.40%AMAT+2.74%1288.HK+0.60%GE+0.98%LRCX+3.22%DELL+2.37%0005.HK-5.56%HSBA.L-6.86%NVS+1.78%NZDJPY+0.69%NZDMXN+0.64%USDJPY+0.61%AUDJPY+0.58%EURNZD-0.55%NZDCHF+0.49%CADJPY+0.49%EURUSD-0.46%AUDDKK+0.44%EURSEK-0.44%EURAUD-0.42%NZDSGD+0.42%USDCHF+0.41%GBPTRY+0.41%AUDCHF+0.40%GBPNZD-0.40%GBPUSD-0.33%GBPHKD+0.32%CHFSEK-0.32%NOKJPY+0.31%EURNOK-0.31%EURCAD-0.30%GBPAUD-0.30%GBPMXN-0.28%CADCHF+0.28%GBPJPY+0.27%EURCNH-0.24%AUDSGD+0.24%USDSEK-0.23%USDMXN+0.23%EURHKD-0.22%USDDKK+0.21%CHFJPY+0.21%USDPLN+0.21%NZDCAD+0.21%GBPCAD-0.21%EURZAR-0.20%EURSGD-0.20%SGDJPY+0.19%CHFNOK-0.18%USDTRY+0.18%EURJPY+0.17%USDILS+0.16%USDCAD+0.14%AUDNOK+0.13%EURGBP-0.12%AUDNZD-0.11%AUDCAD+0.10%USDNOK-0.10%GBPSGD-0.09%GBPZAR-0.08%CHFSGD-0.07%GBPCHF+0.07%NZDUSD+0.07%EURCHF-0.06%USDTHB-0.04%USDCOP-0.04%USDHKD+0.03%AUDUSD-0.03%USDCNH-0.03%USDZAR+0.03%USDSGD+0.01%EURCZK+0.01%PLNJPY+0.01%EURPLN0.00%EURDKK0.00%COFFEE-1.83%COCOA+1.20%SUGAR+1.02%HG1+0.94%XPTUSD-0.71%XAGUSD-0.59%GAGUSD-0.59%UKOIL-0.30%USOIL-0.29%GAUUSD+0.15%XAUUSD+0.15%XNGUSD+0.14%BTCUSD+0.54%ETHUSD+23.96%USDTUSD+0.01%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.06%ZECUSDT+3.59%DOGEUSD+20.65%XMRUSDT-0.08%LINKUSD+25.58%BCHUSDT+1.65%XLMUSD+0.04%UNIUSD-0.19%LTCUSD+17.89%SUIUSD+0.83%HBARUSDT-0.82%TONUSD+41.71%TAOUSDT+0.26%AAVEUSD-1.92%DOTUSDT-1.19%ICPUSDT-0.84%ONDOUSDT-0.24%WLDUSDT+0.83%ARBUSDT+0.60%JUPUSDT+0.30%INJUSDT+0.45%ATOMUSDT-0.21%STXUSDT-0.10%TIAUSDT-2.89%PYTHUSDT-2.39%FETUSDT+1.64%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT-0.27%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+1.05%POLUSDT-0.86%AXSUSDT+0.20%EOSUSDT+2.21%FARTCOINUSDT+2.30%DYDXUSDT+0.44%GALAUSDT-0.75%ORDIUSDT+1.02%RONINUSDT+0.02%NOTUSDT+1.92%
MG

Myriad Genetics, Inc. (MYGN)

NASDAQ • Healthcare

$6.02
+$0.19 (+3.4%)
Market closed

Last close at October 26, 2026 at 20:00 UTC

Open$5.82
Day Range$5.78 - $6.07
Avg. Volume (3M)3M
Market Cap$575.8M
52 Week Range
$2.74$8.38
Next EarningsIn 8 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$190.7M100%
Gross Profitminus cost of goods$127M67%

In plain terms: out of every $100 in revenue, Myriad Genetics, Inc. currently loses $23.

Fundamentals & Financials

Revenue (TTM)
$806.6M
Net Income (TTM)
-$112.6M
EPS (TTM)
-$1.19
ROA (TTM)
-17.62%
Current Ratio
2.21
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+300.0%Q1 2026$0.04
-50.0%Q2 2026-$0.09
-331.9%Q3 2026-$0.25
Next

Nov 4

in 8 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -331.9%

Myriad Genetics’ revenue missed expectations in the second fiscal quarter of 2026, reported July 30, 2026, with revenue of $190.7 million trailing the $206.0 million estimate (-7.4%) and falling 10.5% year over year from $213.1 million. Gross profit was about $127.0 million, leaving gross margin at ~67%, while operating loss was roughly $38.9 million and operating margin was -20.4%. The company posted net income of around -$43.2 million, improving 86.9% from net income of -$330.5 million a year ago. Cash generation remained negative, with negative operating cash flow of roughly $8.3 million. For the next period, consensus calls for EPS of -$0.21 on revenue of $191.4 million.

Next report — what to expect

Myriad Genetics, Inc. (MYGN) reports next on November 2, 2026. Wall Street expects EPS of -$0.16 on revenue of $191.4 million. For trailing context, revenue fell -10.5% year over year last quarter. MYGN has beaten EPS in 4 of 8 most recent quarters, so focus will be on delivery versus these consensus levels.

View full earnings history

About Myriad Genetics, Inc.

Myriad Genetics, Inc. (NASDAQ: MYGN) develops and sells molecular diagnostic tests in healthcare, focused on medical diagnostics and research across oncology, women's health, and pharmacogenomics. In FY2025, Myriad generated $824.5 million of revenue. Its menu spans hereditary cancer, tumor profiling, prenatal screening, carrier screening, and medication-selection testing.

Name
Myriad Genetics, Inc.
CEO
Samraat S. Raha
Website
www.myriad.com
Industry
Healthcare
Year Founded
1991
Employees
2,700

Today's Snapshot

AI-generated

MYGN closed 3.4% higher at 6.02.

Trading Volume

Below 10d avg (4.4M)

1.4M

vs S&P 500 Today

Outperforming Market

+2.74%

Updated: October 27, 2026 at 12:26 UTC

Technical Indicators

6 Buy0 Neutral2 Sell
MYGN exhibits a robust technical posture with the price near 6.02 and ADX around 43.73 signaling strong trend strength. Momentum is mixed—RSI is overbought but CCI and MACD are positive—while the stock sits comfortably above its short-, medium- and 200-day moving averages, confirming a broad-based bullish alignment. Volume patterns are supportive, as OBV is positive, and the pivot at 5.76 lies below the market. Volatility is elevated with ATR about 0.37, reflecting bigger intraday swings. Technical takeaway: trend confirmation and moving averages underpin a strong-buy technical view.
All signals
  • EMA (5 indicators)$4.36 - $5.20
    Buy
  • RSI (14)76.53
    Sell
  • Stochastic %K (14, 3, 3)93.88
    Sell
  • MACD Level (12, 26)0.47
    Buy

Peers & Related Assets

NTRANatera, Inc.
$404.9+0.2%
GHGuardant Health, Inc.
$173.25+2.5%
QGENQiagen N.V.
$50.37-0.0%
VCYTVeracyte, Inc.
$48.2+0.6%
NEONeoGenomics, Inc.
$16.69+0.6%
FLGTFulgent Genetics, Inc.
$20.22+0.6%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.